Login to Your Account



Financings Roundup

Allos Raising $56.6M Publicly to Support Lymphoma Study

By Catherine Hollingsworth


Tuesday, May 27, 2008
Allos Therapeutics Inc. said it expects to net about $56.6 million from a public offering of 10.8 million shares of common stock priced at $5.64 per share, the proceeds of which will help fund clinical trials of the company's lymphoma product. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription